Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > AMAG Pharmaceuticals, Inc. Announces Addition of Joseph V. Bonventre, M.D., Ph. D. to Board of Directors

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced the appointment of Joseph V. Bonventre, M.D., Ph.D. to the Company's Board of Directors.

AMAG Pharmaceuticals, Inc. Announces Addition of Joseph V. Bonventre, M.D., Ph. D. to Board of Directors

Cambridge, MA | Posted on February 27th, 2008

Dr. Bonventre holds appointments as the Robert H. Ebert Professor of Medicine at Harvard Medical School, in Cambridge, MA, and Professor of Health Sciences and Technology at Massachusetts Institute of Technology (MIT). He is Director of the Renal Division at Brigham & Women's Hospital in Boston, MA. Dr. Bonventre is a member of the Council of the American Society of Nephrology (ASN). He is Chair of the Kidney Group of the Harvard Stem Cell Initiative, co-chair of the Stem Cell, Regenerative Medicine and Tissue Engineering Center of the Brigham and Women's Hospital Research Institute and co-chair of the Technology in Medicine Initiative at the Brigham and Women's Hospital.

"We are delighted to have Dr. Bonventre join our Board at this important time for the Company. His academic experience, participation on scientific and medical advisory boards of several companies and his long-standing involvement with the ASN further strengthens our organization," commented Brian J.G. Pereira, M.D., President and Chief Executive Officer of AMAG Pharmaceuticals, Inc. "We look forward to Dr. Bonventre's contributions and welcome him to the Board," concluded Dr. Pereira.

Prior to his current appointments at Harvard Medical School and MIT, Dr. Bonventre served as Co-Director, Harvard-MIT Division of Health Sciences and Technology. In addition to his B.S. with distinction in Engineering Physics from Cornell University, Dr. Bonventre holds M.D. and Ph.D. degrees in Biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary's College and from the Norwegian Institute of Science and Technology. Dr. Bonventre completed his internship and residencies in Medicine at Massachusetts General Hospital. He is published widely on kidney injury and repair.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration in December 2007 which was accepted for filing in February 2008.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Kristen Galfetti, 617-498-3362

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Nanomedicine

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Announcements

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Aculon Hires New Business Development Director December 19th, 2014

Nanomedicine expert joins Rice faculty: Gang Bao combines genetic, nano and imaging techniques to fight disease December 17th, 2014

Nexeon Attracts ex-Nokia Product Executive to its Board of Directors December 15th, 2014

Arrowhead Appoints Patrick O'Brien as General Counsel December 4th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE